Brand Name
Beovu
Generic Name
Brolucizumab
View Brand Information FDA approval date: July 26, 2018
Form: Injection
What is Beovu (Brolucizumab)?
BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor inhibitor indicated for the treatment of: Neovascular Age-Related Macular Degeneration .
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Treatment of Severe Diabetic Macular Oedema With Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser When the Thickness of the Central Retina Goes Below 400 Microns: Pragmatic Randomised Equivalence Trial
Summary: The macula is the centre of the retina; it gives central sight, colour and fine detail. People with diabetes may develop diabetic macular oedema (DMO). In DMO, fluid leaks from blood vessels and builds up at the macula, causing sight loss. DMO can be mild or severe; this is determined by measuring, in microns (µm), how thick the macula is. One µm is one-thousandth of a millimetre. People presentin...
Regulatory Post-Marketing Surveillance (rPMS) Study for Brolucizumab(Beovu ® Injection, Beovu ®Prefilled Syringe)
Summary: This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.